Fulcrum Pharma PLC
13 October 2000
FULCRUM PHARMA DEVELOPMENTS LTD
SIGNS DEVELOPMENT AGREEMENT WITH XENOVA GROUP PLC
Hemel Hempstead, UK - Fulcrum Pharma plc (LSE: FUL), the independent, drug
development company, announced today that the company has entered into a
multi-year development agreement with Xenova Group plc (LSE: XEN; Nasdaq:
XNVA) for the further development of a next-generation oncology product
currently undergoing pre-clinical evaluation and anticipated to enter human
clinical trials in 2001.
Dr Jon Court, Fulcrum's Chief Executive Officer, welcomed this agreement,
'This is a significant contract for Fulcrum from which we expect to build a
long term relationship with Xenova. This relationship gives Xenova greater
flexibility in out-sourcing its development requirements. Fulcrum will provide
infrastructure and expertise, allowing the immediate start up of the planned
programme, without Xenova having to increase its internal resources.'
For further information, please contact :
Fulcrum Pharma PLC
Jon Court, Chief Executive 0700 392 1103
Neil Oughton, Business Development Director 0700 392 1105
Nicola How / Louise Bolton 0207 466 5000
Notes to Editors:
Fulcrum Pharma plc is an independent, drug development company that is the
first to offer global virtual drug development and strategic outsourcing
services to the pharmaceutical industry.
The Company has expertise in the design, execution and delivery of drug
development programmes and relies on state of the art information technology
and infrastructure in the supply of its services.
Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.
Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange having successfully floated earlier this year.